(Total Views: 535)
Posted On: 06/03/2019 12:25:41 PM
Post# of 74

$SGEN News Article - Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer https://marketwirenews.com/news-releases/seat...88382.html


My Twitter: WhyteStocks